BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients

被引：31

作者：

Gilli, Stefanie ^{[1
]}

Novak, Urban ^{[1
]}

Taleghani, Behrouz Mansouri ^{[2
]}

Baerlocher, Gabriela M. ^{[2
]}

Leibundgut, Kurt ^{[3
]}

Banz, Yara ^{[4
]}

Zander, Thilo ^{[5
]}

Betticher, Daniel ^{[6
]}

Egger, Thomas ^{[7
]}

Rauch, Daniel ^{[8
]}

Pabst, Thomas ^{[1
]}

机构：

[1] Univ Hosp Bern, Dept Med Oncol, CH-3010 Bern, Switzerland

[2] Univ Hosp Bern, Dept Hematol, Bern, Switzerland

[3] Univ Hosp Bern, Dept Pediat Hematooncol, Inselspital, Bern, Switzerland

[4] Univ Bern, Inst Pathol, Bern, Switzerland

[5] Kantonsspital, Dept Oncol, Luzern, Switzerland

[6] Kantonsspital, Dept Oncol, Fribourg, Switzerland

[7] Kantonsspital, Dept Oncol, Solothurn, Switzerland

[8] Regionalspital, Dept Oncol, Thun, Switzerland

来源：

ANNALS OF HEMATOLOGY | 2017年 / 96卷 / 03期

关键词：

Autologous; Stem cell; Transplantation; Bendamustine; Lymphoma; Beam; BeEAM; BCNU; Prognosis; Survival; High dose; Chemotherapy; STEM-CELL TRANSPLANTATION; NON-HODGKINS-LYMPHOMA; HIGH-DOSE CHEMOTHERAPY; BONE-MARROW-TRANSPLANTATION; MULTICENTER PHASE-II; B-CELL; MANTLE CELL; PLUS RITUXIMAB; CONVENTIONAL CHEMOTHERAPY; INTENSIFIED CHEMOTHERAPY;

D O I：

10.1007/s00277-016-2900-y

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (> 20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.

引用

页码：421 / 429

页数：9

共 37 条

[11] Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes [J].

Flowers, Christopher R. ;

Costa, Luciano J. ;

Pasquini, Marcelo C. ;

Le-Rademacher, Jennifer ;

Lill, Michael ;

Shore, Tsiporah B. ;

Vaughan, William ;

Craig, Michael ;

Freytes, Cesar O. ;

Shea, Thomas C. ;

Horwitz, Mitchell E. ;

Fay, Joseph W. ;

Mineishi, Shin ;

Rondelli, Damiano ;

Mason, James ;

Braunschweig, Ira ;

Ai, Weiyun ;

Yeh, Rosa F. ;

Rodriguez, Tulio E. ;

Flinn, Ian ;

Comeau, Terrance ;

Yeager, Andrew M. ;

Pulsipher, Michael A. ;

Bence-Bruckler, Isabelle ;

Laneuyille, Pierre ;

Bierman, Philip ;

Chen, Andy I. ;

Kato, Kazunobu ;

Wang, Yanlin ;

Xu, Cong ;

Smith, Angela J. ;

Waller, Edmund K. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (07) :1197-1205

[12] Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: Results from a phase II multicenter, single-agent study [J].

Friedberg, Jonathan W. ;

Cohen, Philip ;

Chen, Ling ;

Robinson, K. Sue ;

Forero-Torres, Andres ;

La Casce, Ann S. ;

Fayad, Luis E. ;

Bessudo, Alberto ;

Camacho, Elber S. ;

Williams, Michael E. ;

Van der Jagt, Richard H. ;

Oliver, Jennifer W. ;

Cheson, Bruce D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :204-210

[13] Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era [J].

Gisselbrecht, Christian ;

Glass, Bertram ;

Mounier, Nicolas ;

Gill, Devinder Singh ;

Linch, David C. ;

Trneny, Marek ;

Bosly, Andre ;

Ketterer, Nicolas ;

Shpilberg, Ofer ;

Hagberg, Hans ;

Ma, David ;

Briere, Josette ;

Moskowitz, Craig H. ;

Schmitz, Norbert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) :4184-4190

[14]

GRIBBEN JG, 1989, BLOOD, V73, P340

[15] Cell-based therapies for osteonecrosis of the femoral head [J].

Jones, Kevin B. ;

Seshadri, Tara ;

Krantz, Roselynn ;

Keating, Armand ;

Ferguson, Peter C. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (10) :1081-1087

[16] Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation-Based Conditioning for Poor-Risk Diffuse Large Cell Lymphoma [J].

Krishnan, Amrita ;

Palmer, Joycelynne M. ;

Tsai, Ni-Chun ;

Simpson, Jennifer R. ;

Nademanee, Auayporn ;

Raubitschek, Andrew ;

Thomas, Sandra H. ;

Forman, Stephen J. .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (03) :441-450

[17] Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant [J].

Lane, Andrew A. ;

Armand, Philippe ;

Feng, Yang ;

Neuberg, Donna S. ;

Abramson, Jeremy S. ;

Brown, Jennifer R. ;

Fisher, David C. ;

LaCasce, Ann S. ;

Jacobsen, Eric D. ;

McAfee, Steven L. ;

Spitzer, Thomas R. ;

Freedman, Arnold S. ;

Chen, Yi-Bin .

LEUKEMIA & LYMPHOMA, 2012, 53 (06) :1130-1136

[18] Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents [J].

Leoni, Lorenzo M. ;

Bailey, Brandi ;

Reifert, Jack ;

Bendall, Heather H. ;

Zeller, Robert W. ;

Corbeil, Jacques ;

Elliott, Gary ;

Niemeyer, Christina C. .

CLINICAL CANCER RESEARCH, 2008, 14 (01) :309-317

[19] BEAM CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKINS-LYMPHOMA [J].

MILLS, W ;

CHOPRA, R ;

MCMILLAN, A ;

PEARCE, R ;

LINCH, DC ;

GOLDSTONE, AH .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (03) :588-595

[20] Conditioning regimens before transplantation in patients with aggressive non-Hodgkin's lymphoma [J].

Mounier, N ;

Gisselbrecht, C .

ANNALS OF ONCOLOGY, 1998, 9 :15-21

← 1 2 3 4 →